Angefügt die bereits bekannte Anfrage der kanadischen Onkologin und die Antwort von Robert Smith, dem Vizepräsidenten.
Aus Datenschutzgründen habe ich persönliche Daten unkenntlich gemacht:
A, M.Sc., PhD Universitätsklinikum Gastroenterology, Hepatology and Infectious Diseases Email: @uni-de
Begin forwarded message:
From: Robert Smith
Subject: RE: ACS colorectal cancer screening
Date: July 11, 2018 at 7:44:06 PM GMT+2
To: A.XXX
Dear Axxx,
Sorry to be so late in responding. We normally update guidelines every 5 years, but it is not uncommon that this interval is extended due to the absence of new data, or waiting for the publication of critical data. This approach, admittedly, was better suited to the slower pace of discovery in the past, and so were starting to explore ways in which molecular testing that could be used in cancer screening could be considered more expeditiously. The new IOM guideline development guidelines was not much help with this new imperative. As you saw in the guideline, the guideline development group chose not to include mSept 9 among the options for screening. Im sure the guideline development group will revisit the existing data on mSept 9 in the next update.
Best regards,
Robert Smith
Robert Smith, PHD | Vice President, Cancer Screening
American Cancer Society, Inc.
250 xxx
Atlanta, GA 30303
Phone: 404.xxx | Mobile: 4xxx | Fax: xxx
cancer.org | 1.800.227.2345
This message (including any attachments) is intended exclusively for the individual to whom it is addressed and may contain proprietary, protected, or confidential information. If you are not the named addressee, you are not authorized to read, print, copy, or disseminate this message or any part of it. If you have received this message in error, please notify the sender immediately.
From: Axxx [mailto:Axxx@uni-xxx.de] Sent: Thursday, June 21, 2018 4:10 AM To: Robert Smith Subject: ACS colorectal cancer screening
Dear Dr. Smith,
I read with interest your article (Wolf metal., 2018) describing the recent guideline update from the ACS regarding the colorectal cancer screening. I am a cancer researcher from Düsseldorf interested in liquid biopsies and was curious to know how often the ACS makes such updates and reconsiders new technologies such as the methylated SEPT9 test for routine screening? Thanks very much in advance,
A.xxx
Axxx Universitätsklinikumxxx
|